Search

Your search keyword '"Balakirouchenane, David"' showing total 19 results
Start Over Author "Balakirouchenane, David"
19 results on '"Balakirouchenane, David"'

1. Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients

Author

Puszkiel, Alicja, Bianconi, Guillaume, Pasquiers, Blaise, Balakirouchenane, David, Arrondeau, Jennifer, Boudou-Rouquette, Pascaline, Bretagne, Marie-Claire, Salem, Joe-Elie, Declèves, Xavier, Vidal, Michel, Kramkimel, Nora, Guegan, Sarah, Aractingi, Selim, Huillard, Olivier, Alexandre, Jérôme, Wislez, Marie, Goldwasser, François, and Blanchet, Benoit

Published
2024
Full Text
View/download PDF

3. Hydroxychloroquine sulfate: A novel treatment for lipin-1 deficiency?

Author

Renard, Perrine, Caccavelli, Laure, Legendre, Antoine, Tuchmann-Durand, Caroline, Balakirouchenane, David, Blanchet, Benoit, Narjoz, Céline, Straube, Marjolène, Hubas, Arnaud, Garros, Alexa, Mention, Karine, Bednarek, Nathalie, Goudin, Nicolas, Broissand, Christine, Schlatter, Joel, Cisternino, Salvatore, Cagnard, Nicolas, van Endert, Peter, Diana, Julien, de Calbiac, Hortense, and de Lonlay, Pascale

Published
2023
Full Text
View/download PDF

4. Decrease in anticortisolic drmg osilodrostat plasma exposure in patients treated with mitotane for adrenocortical carcinoma

Author

Thomeret, Louis, primary, Puszkiel, Alicja, additional, Balakirouchenane, David, additional, Bouys, Lucas, additional, Poirier, Jonathan, additional, Berthon, Annabel, additional, Ragazzon, Bruno, additional, Jouinot, Anne, additional, Guignat, Laurence, additional, Bessiene, Laura, additional, Libe, Rossella, additional, Bricaire, Leopoldine, additional, Leguy, Marie-Clemence, additional, Guibourdenche, Jean, additional, Groussin-Rouiller, Lionel, additional, Assie, Guillaume, additional, Blanchet, Benoit, additional, Bertherat, Jerome, additional, and Bonnet-Serrano, Fideline, additional

Published
2024
Full Text
View/download PDF

5. Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management

Author

Bellesoeur, Audrey, Gataa, Ithar, Jouinot, Anne, Mershati, Sarah El, Piketty, Anne-Catherine, Tlemsani, Camille, Balakirouchenane, David, Monribot, Anthia, Vidal, Michel, Batista, Rui, de Percin, Sixtine, Villeminey, Clémentine, Alexandre, Jérôme, Goldwasser, François, Blanchet, Benoit, Boudou-Rouquette, Pascaline, and Thomas-Schoemann, Audrey

Published
2021
Full Text
View/download PDF

6. A Rapid Lc-Ms/Ms Method for the Simultaneous Quantification of Ivacaftor, Lumacaftor, Elexacaftor, Tezacaftor, Hexyl-Methyl Ivacaftor and Ivacaftor Carboxylate in Human Plasma

Author

ZHENG, Yi, primary, ROUILLON, Steeve, additional, KHEMAKHEM, Mohamed, additional, BALAKIROUCHENANE, David, additional, LUI, Gabrielle, additional, ABDALLA, Seef, additional, SANOUFI, Mohammed Rohi, additional, SAUVAITRE, Lucie, additional, THEBAULT, Laure, additional, HIRT, Déborah, additional, Treluyer, Jean-Marc, additional, GANA, Inès, additional, BENABOUD, Sihem, additional, and FROELICHER-BOURNAUD, Léo, additional

Published
2024
Full Text
View/download PDF

7. Decrease in anticortisolic drug osilodrostat plasma exposure in patients treated with mitotane for an adrenocortical carcinoma

Author

Thomeret, Louis, primary, Puszkiel, Alicja, additional, Balakirouchenane, David, additional, Bouys, Lucas, additional, Poirier, Jonathan, additional, Berthon, Annabel, additional, Ragazzon, Bruno, additional, Jouinot, Anne, additional, Guignat, Laurence, additional, Bessiene, Laura, additional, Libe, Rossella, additional, Bricaire, Leopoldine, additional, Groussin, Lionel, additional, Assie, Guillaume, additional, Blanchet, Benoit, additional, Bonnet-Serrano, Fideline, additional, and Bertherat, Jerome, additional

Published
2023
Full Text
View/download PDF

8. Pharmacokinetics/Pharmacodynamics of dabrafenib and trametinib for redifferentiation and treatment of radioactive-iodine-resistant mutated advanced differentiated thyroid cancer

Author

Balakirouchenane, David, primary, Seban, Romain, additional, Groussin, Lionel, additional, Puszkiel, Alicja, additional, Cottereau, Anne Segolene, additional, Clerc, Jerome, additional, Vidal, Michel, additional, Goldwasser, Francois, additional, Arrondeau, Jennifer, additional, Blanchet, Benoit, additional, and Huillard, Olivier, additional

Published
2023
Full Text
View/download PDF

9. LC-MS/MS method for simultaneous quantification of osilodrostat and metyrapone in human plasma from patients treated for Cushing’s Syndrome

Author

Balakirouchenane, David, primary, Vasseur, Axelle, additional, Bonnet-Serrano, Fidéline, additional, Choi, Minna, additional, Khoudour, Nihel, additional, Puszkiel, Alicja, additional, Groussin, Lionel, additional, Vidal, Michel, additional, Declèves, Xavier, additional, Bertherat, Jérôme, additional, and Blanchet, Benoit, additional

Published
2023
Full Text
View/download PDF

10. Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma

Author

Isberner, Nora, primary, Gesierich, Anja, additional, Balakirouchenane, David, additional, Schilling, Bastian, additional, Aghai-Trommeschlaeger, Fatemeh, additional, Zimmermann, Sebastian, additional, Kurlbaum, Max, additional, Puszkiel, Alicja, additional, Blanchet, Benoit, additional, Klinker, Hartwig, additional, and Scherf-Clavel, Oliver, additional

Published
2022
Full Text
View/download PDF

11. Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer

Author

Rodier, Thomas, primary, Puszkiel, Alicja, additional, Cardoso, Evelina, additional, Balakirouchenane, David, additional, Narjoz, Céline, additional, Arrondeau, Jennifer, additional, Fallet, Vincent, additional, Khoudour, Nihel, additional, Guidi, Monia, additional, Vidal, Michel, additional, Declèves, Xavier, additional, Csajka, Chantal, additional, Alexandre, Jérôme, additional, Cadranel, Jacques, additional, Fabre, Elizabeth, additional, Wislez, Marie, additional, Goldwasser, François, additional, and Blanchet, Benoit, additional

Published
2022
Full Text
View/download PDF

12. Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients

Author

Minot-This, Marie-Sophie, primary, Boudou-Rouquette, Pascaline, additional, Jouinot, Anne, additional, de Percin, Sixtine, additional, Balakirouchenane, David, additional, Khoudour, Nihel, additional, Tlemsani, Camille, additional, Chauvin, Jonathan, additional, Thomas-Schoemann, Audrey, additional, Goldwasser, François, additional, Blanchet, Benoit, additional, and Alexandre, Jérôme, additional

Published
2022
Full Text
View/download PDF

13. Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study

Author

Velev, Maud, primary, Puszkiel, Alicja, additional, Blanchet, Benoit, additional, de Percin, Sixtine, additional, Delanoy, Nicolas, additional, Medioni, Jacques, additional, Gervais, Claire, additional, Balakirouchenane, David, additional, Khoudour, Nihel, additional, Pautier, Patricia, additional, Leary, Alexandra, additional, Ajgal, Zahra, additional, Hirsch, Laure, additional, Goldwasser, François, additional, Alexandre, Jerome, additional, and Beinse, Guillaume, additional

Published
2021
Full Text
View/download PDF

15. Prevalence of Drug-Drug Interactions in Sarcoma Patients: Key Role of the Pharmacist Integration for Toxicity Risk Management

Author

Bellesoeur, Audrey, primary, Gataa, Ithar, additional, Jouinot, Anne, additional, Mershati, Sarah El, additional, Piketty, Anne Catherine, additional, Tlemsani, Camille, additional, Balakirouchenane, David, additional, Monribot, Anthia, additional, Vidal, Michel, additional, Batista, Rui, additional, Percin, Sixtine De, additional, Villeminey, Clementine, additional, Alexandre, Jerome, additional, Goldwasser, Francois, additional, Blanchet, Benoit, additional, Boudou-Rouquette, pascaline, additional, and Thomas-Schoemann, Audrey, additional

Published
2021
Full Text
View/download PDF

17. Pharmacogenetic—Whole blood and intracellular pharmacokinetic—Pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients

Author

Tron, Camille, Woillard, Jean-Baptiste, Houssel-Debry, Pauline, David, Véronique, Jezequel, Caroline, Rayar, Michel, Balakirouchenane, David, Blanchet, Benoit, Debord, Jean, Petitcollin, Antoine, Roussel, Mickaël, Verdier, Marie-Clémence, Bellissant, Eric, Lemaitre, Florian, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Pharmacology and Toxicology [Limoges], CHU Limoges, Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation (IPPRITT), CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Université de Limoges (UNILIM), Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Department of Molecular Genetics and Genomics [Rennes], Institut de Génétique et Développement de Rennes (IGDR), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Pharmacokinetics and Pharmacochemistry Department [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Chimie Organique, Médicinale et Extractive et Toxicologie Expérimentale (COMETE - UMR 8638), Université Paris Descartes - Paris 5 (UPD5)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Haematology Laboratory [Rennes], Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Bodescot, Myriam

Subjects
Male, Heredity, ATP Binding Cassette Transporter, Subfamily B, Genotype, Physiology, chemical and pharmacologic phenomena, Surgical and Invasive Medical Procedures, Polymorphism, Single Nucleotide, Tacrolimus, Molecular Genetics, Digestive System Procedures, Medicine and Health Sciences, Genetics, Cytochrome P-450 CYP3A, Humans, Pharmacokinetics, Molecular Biology, Aged, Pharmacology, Immunosuppression Therapy, Transplantation, Biology and Life Sciences, Drugs, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Organ Transplantation, Hematology, Middle Aged, Immunosuppressives, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Body Fluids, Liver Transplantation, Pharmacogenomic Testing, Blood Counts, stomatognathic diseases, Genetic Mapping, Blood, Pharmacodynamics, Hematocrit, Haplotypes, Pharmacogenetics, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Leukocytes, Mononuclear, Female, Anatomy, Immunosuppressive Agents, Research Article
Abstract

International audience; Tacrolimus (TAC) is the cornerstone of immunosuppressive therapy in liver transplantation. This study aimed at elucidating the interplay between pharmacogenetic determinants of TAC whole blood and intracellular exposures as well as the pharmacokinetic-pharmacodynamic relationship of TAC in both compartments. Complete pharmacokinetic profiles (Predose, and 20 min, 40 min, 1h, 2h, 3h, 4h, 6h, 8h, 12h post drug intake) of twice daily TAC in whole blood and peripheral blood mononuclear cells (PBMC) were collected in 32 liver transplanted patients in the first ten days post transplantation. A non-parametric population pharmacokinetic model was applied to explore TAC pharmacokinetics in blood and PBMC. Concurrently, calcineurin activity was measured in PBMC. Influence of donor and recipient genetic polymorphisms of ABCB1, CYP3A4 and CYP3A5 on TAC exposure was assessed. Recipient ABCB1 polymorphisms 1199G>A could influence TAC whole blood and intracellular exposure (p

Published
2020

18. Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma

Author

Balakirouchenane, David, primary, Guégan, Sarah, additional, Csajka, Chantal, additional, Jouinot, Anne, additional, Heidelberger, Valentine, additional, Puszkiel, Alicja, additional, Zehou, Ouidad, additional, Khoudour, Nihel, additional, Courlet, Perrine, additional, Kramkimel, Nora, additional, Lheure, Coralie, additional, Franck, Nathalie, additional, Huillard, Olivier, additional, Arrondeau, Jennifer, additional, Vidal, Michel, additional, Goldwasser, Francois, additional, Maubec, Eve, additional, Dupin, Nicolas, additional, Aractingi, Selim, additional, Guidi, Monia, additional, and Blanchet, Benoit, additional

Published
2020
Full Text
View/download PDF

19. Pharmacogenetic—Whole blood and intracellular pharmacokinetic—Pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients.

Author

Tron, Camille, Woillard, Jean-Baptiste, Houssel-Debry, Pauline, David, Véronique, Jezequel, Caroline, Rayar, Michel, Balakirouchenane, David, Blanchet, Benoit, Debord, Jean, Petitcollin, Antoine, Roussel, Mickaël, Verdier, Marie-Clémence, Bellissant, Eric, and Lemaitre, Florian

Subjects
LIVER transplantation, BLOOD, BLOOD cells, GENETIC polymorphisms, INDIVIDUALIZED medicine
Abstract

Tacrolimus (TAC) is the cornerstone of immunosuppressive therapy in liver transplantation. This study aimed at elucidating the interplay between pharmacogenetic determinants of TAC whole blood and intracellular exposures as well as the pharmacokinetic-pharmacodynamic relationship of TAC in both compartments. Complete pharmacokinetic profiles (Predose, and 20 min, 40 min, 1h, 2h, 3h, 4h, 6h, 8h, 12h post drug intake) of twice daily TAC in whole blood and peripheral blood mononuclear cells (PBMC) were collected in 32 liver transplanted patients in the first ten days post transplantation. A non-parametric population pharmacokinetic model was applied to explore TAC pharmacokinetics in blood and PBMC. Concurrently, calcineurin activity was measured in PBMC. Influence of donor and recipient genetic polymorphisms of ABCB1, CYP3A4 and CYP3A5 on TAC exposure was assessed. Recipient ABCB1 polymorphisms 1199G>A could influence TAC whole blood and intracellular exposure (p<0.05). No association was found between CYP3A4 or CYP3A5 genotypes and TAC whole blood or intracellular concentrations. Finally, intra-PBMC calcineurin activity appeared incompletely inhibited by TAC and less than 50% of patients were expected to achieve intracellular IC50 concentration (100 pg/millions of cells) at therapeutic whole blood concentration (i.e.: 4–10 ng/mL). Together, these data suggest that personalized medicine regarding TAC therapy might be optimized by ABCB1 pharmacogenetic biomarkers and by monitoring intracellular concentration whereas the relationship between intracellular TAC exposure and pharmacodynamics biomarkers more specific than calcineurin activity should be further investigated. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results